Marianne van der Steen is Professor of Entrepreneurship in Healthcare at the Technology-inspired Institute of Regenerative Medicine (MERLN), Faculty of Health, Medicine and Life Sciences, Maastricht University. She has been appointed director of RegMed XB and member of the board of governors of RegMed XB foundation. Marianne van der Steen received her PhD degree in 1999 from Twente University. Her research focus is on biomedical entrepreneurship, specifically on the scaling-up of ventures. At MERLN, she is responsible for biomedical entrepreneurship valorization, training and education from the lab to a spin-off company.
In addition, she is the founding director of executive life sciences entrepreneurship programs such as the Global Investor Forum, the Global Scale-up Program and the executive Master MBI Life Sciences & Health (currently member of the advisory board). Since 2006, she has been involved in life sciences start-ups, served in early stage start-up investor boards and national and international advisory boards related to entrepreneurship and valorization in the Netherlands, Belgium and the United States.
Frank P. Luyten, MD, PhD is board certified Rheumatologist, tenured full Professor and Head of the Division of Rheumatology at the University Hospitals Leuven; Director of the Skeletal Biology & Engineering Research Center, KU Leuven and of Prometheus, the Tissue Engineering Division at the KU Leuven. He obtained his MD, PhD degree and Board Certification in Rheumatology at the University of Ghent, Belgium. He spent his Postdoctoral Training at the National Institute of Dental Research, National Institutes of Health, Bethesda, MD, USA. He became subsequently group leader of the Developmental Biology Unit at the Bone Research Branch, NIDR, NIH, Bethesda, USA. Frank Luyten is also founder, scientific and medical advisor of TiGenix, a Biotech spin-off of the Universities of Leuven and Ghent. He serves as advisor and board member of several biotech companies in the field of Regenerative Medicine.
Vanessa LaPointe is the Scientific Coordinator of RegMed XB. She is also in the tenure track as an Assistant Professor in the MERLN Institute for Technology-Inspired Regenerative Medicine. She first trained as a biomedical engineer at The Johns Hopkins University (USA), but moved into the field of tissue engineering and regenerative medicine during her PhD with Prof. Molly Stevens at Imperial College London. Currently, her group works at the interface of materials science and stem cell biology to better understand how biomaterials can influence cell fate.
Tom Mastenbroek is the Project Manager for RegMedXB. He studied biology at the University of Wageningen and during his master’s education he specialized in cellular differentiation and immunology. In 2016, he obtained his Ph.D. in the field of vascular biology, vessel wall remodelling and thrombosis & haemostasis at Maastricht University under the guidance of Dr. Judith Cosemans and Prof. Johan Heemskerk. In his thesis, he showed for the first time the potential of blood platelets to degrade extracellular matrix and the involvement of platelets in pathological remodelling of the vessel wall after an atherothrombotic event. This concept was further exploited during his PostDoc where he identified novel ways of inhibiting platelet dependent growth factor secretion aiming to block pathological vascular remodelling.
Bianca Beusink is a Project Manager for RegMed XB. After finishing her PhD in the field of multiplex SPR imaging at the University of Twente in the group of Albert van der Berg, she has worked at the EMBL in Heidelberg. The switch from academia to international sales at IBIS Technologies and PerkinElmer allowed her to grow into a team leader position at Bayer Medical Care B.V. before taking up her current position at RegMed XB.
Yvette Aldenhoff is a project manager for RegMedXB. She studied organic chemistry and obtained her PhD in the field of bloodcompatibilty of vascular biomedical polyurethanes at the Maastricht University. After her Phd she worked as a PostDoc at the centre for biomedical research focussing on the development of new biomedical materials. In 2008 she started working as general manager/quality manager for INterface BIOmaterials BV. This life science company developed a proprietary new product for the embolization of uterine fibroids. Furthermore, she was project coordinator of the public/private project KidneyPort which was aimed at developing new methods for detoxification of blood to open pathways to easier, safer, smaller and ultimately for a portable artificial kidney system.
Since 2009 Marcel Hammink has helped dozens of large organizations to optimize their communication with the press and the public. To that effect his company Marcel Hammink Media provides all kinds of goods and services: mediatraining and -advice, films and books. Amongst his customers are: the ministries of defense and justice, RIVM, Trimbos, Eneco, Menzis, TenneT, Universities of Twente and Maastricht, UMCG, Roessingh, Health Valley.
Marcel studied public administration, international relations and journalism (postdoc). He worked as a journalist for 15 years. From 2000-2009 he was senior tv-reporter of Nieuwsuur, the leading current affairs program of Dutch public television, NPO-2. In 2007 he won the RD-Persprijs.
Biography will be added soon